Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML

Clinical trial NCT06268574 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06268574
Sponsor: Ryvu Therapeutics SA
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Acute Myeloid Leukemia (AML)High-risk Myelodysplastic Syndrome

Start date: 2024-01-23
Primary completion: 2026-02-01
Enrollment: 94

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.